Virus Science and Why Virology Isn't Being Done Right

Modern virology operates on assumptions that its own published research does not fully support. This section of the knowledge base examines those assumptions in detail: what it means to isolate a virus, how epidemic causes are determined, what laboratory tests can and cannot detect, and how pharmaceutical and institutional interests shape which explanations receive funding and media coverage.

No epidemic since polio has met Koch's postulates, the foundational criteria for proving a microbe causes a disease, yet the viral explanation is treated as self-evident in each case.
PCR tests amplify gene fragments, not whole viruses. At the cycle thresholds used in COVID-19 testing, the method's own quality standards classify results as unreliable.
Most drugs deployed in epidemic responses, including AZT, Tamiflu, HPA-23 and remdesivir, were approved under emergency conditions with documented toxicity and insufficient evidence of benefit.
Non-viral explanations for mass illness (malnutrition, toxic exposures, pharmaceutical side effects) are consistently present in the evidence and consistently excluded from official investigations.
Vaccine safety trials for every product on standard childhood schedules compare against active compounds, not inert placebos, making independent risk assessment structurally impossible.
Financial conflicts of interest run through every level of the system: advisory bodies, regulatory agencies, academic institutions, and media outlets.

What virology actually claims and what the evidence shows

The standard account of viral disease goes like this: a novel pathogen is identified, its genetic sequence is mapped, tests are developed, drugs and vaccines are approved, and deaths are attributed to the confirmed organism. Each of these steps involves evidentiary standards. The research examined in this knowledge base asks whether those standards are actually being met.

The answer, documented across AIDS, SARS, avian flu, swine flu, hepatitis C, BSE, measles, and COVID-19, is that they frequently are not. Purification of viral particles, the prerequisite for proving an organism exists and causes harm, has been skipped or acknowledged as incomplete in the key papers behind major epidemic claims. PCR tests detect gene sequences, not confirmed disease-causing agents. Antibody tests react to multiple proteins and cannot diagnose a specific infection. The researchers who built the original HIV, SARS, and SARS-CoV-2 detection papers acknowledged these gaps when asked directly.

The role of non-viral causes

Across every epidemic studied, alternative explanations for mass illness were present in the evidence and absent from official investigations. During the early AIDS epidemic, the patients who developed immune collapse were overwhelmingly heavy users of nitrite inhalants (poppers), multiple pharmaceutical drugs, and had histories of severe nutritional deficiency. These were not incidental background factors. They were documented immunosuppressants with clear biological mechanisms.

The same pattern appeared with BSE (organophosphate pesticides used in cattle dips), avian flu outbreaks (factory farming conditions producing severe respiratory illness without requiring viral transmission), and COVID-19 mortality (patients receiving combinations of drugs, several of which had documented lethal adverse effects, with deaths attributed to the virus). This is not an argument that viruses do not exist or never cause harm. It is an argument that when institutional and financial pressure favours a particular explanation, the evidentiary standards required to establish it are relaxed and the alternatives stop receiving investigation.

Drugs approved without adequate evidence

A recurring pattern across AIDS, SARS, avian flu, swine flu, and COVID-19 is the emergency approval of antiviral drugs under conditions that bypassed normal safety and efficacy evaluation. AZT, the first AIDS drug approved by the FDA, was cleared after a trial so brief and poorly controlled that the lead researcher's own data suggested it was lethally toxic rather than beneficial. HPA-23, administered to AIDS patients in France in the mid-1980s, had no proven efficacy and documented liver-destroying effects.

Tamiflu, stockpiled by governments at a cost of billions, was shown by a systematic review of complete trial data to provide no meaningful benefit for influenza. Remdesivir, promoted by senior US government officials from the White House in 2020, had its primary outcome measure changed mid-trial, and the original Chinese trial was stopped early because patients in the treatment group were experiencing significantly more adverse events. In each case, the drug was presented to the public as a medical breakthrough. In each case, the evidence did not withstand scrutiny.

How epidemic narratives are built

The knowledge base documents a consistent mechanism: emotional imagery and personal stories of recognisable individuals make abstract statistical claims feel real to the public. Rock Hudson's AIDS diagnosis in 1985, the coffin images from Italian hospitals in 2020, the avian flu mortality projections tied to photographs of dying birds. Each provided the emotional anchor that made a viral narrative feel confirmed, independent of what the underlying data actually showed.

Statistics professor Gerd Bosbach described this in the context of COVID-19: when images of intensive care units and military vehicles transporting the dead are broadcast continuously, the emotional effect substantially exceeds anything the stated mortality figures would justify on their own. This does not require deliberate deception. It is how human cognition processes risk. But it does require that media organisations and public health bodies apply more rigorous methodological standards when the emotional signal is strongest, which is precisely when they historically have applied fewer.

Vaccine safety and the missing placebo

Every pharmaceutical product approved by drug regulators in the major economies must demonstrate its safety profile through comparison with a genuinely inert placebo. Vaccines are structurally exempt from this requirement. Trials for products on standard childhood schedules compare vaccinated groups against groups receiving other vaccines or adjuvant-containing preparations, rather than saline. This means adverse events common to both arms of a trial are invisible to the analysis.

The consequence is that the claimed safety profiles for vaccines cannot be independently verified from the approval data. Several researchers cited in this knowledge base requested the underlying safety datasets from regulatory bodies and vaccine manufacturers. In multiple cases, the data either did not exist in the form claimed or was not provided. One analysis suggested fewer than one percent of adverse events reach official reporting systems.

Institutional structure and financial incentives

The knowledge base does not argue for conspiracy. It argues for a structural problem: the institutions responsible for identifying infectious threats, approving treatments, and communicating risk to the public are substantially funded by the pharmaceutical companies whose products they evaluate. Advisory committees include members with undisclosed financial relationships to manufacturers. Academic institutions that produce the modelling used to justify pandemic responses receive large grants from foundations with pharmaceutical investment portfolios.

These relationships do not make individual scientists dishonest. They create systematic incentive structures that make certain findings more publishable, certain questions less likely to be asked, and certain dissenting voices more likely to be dismissed without engagement. The researchers and clinicians who raised evidence-based objections to the consensus during AIDS, swine flu, and COVID-19 were not refuted in the published literature. They were characterised as dangerous or ignored.

What a more rigorous approach would require

The standard the knowledge base applies is not unusual. It is the standard that Koch articulated in the 1880s, that Cochrane methodology applies to drug trials, and that is taught in every introductory epidemiology course:

Purify the candidate pathogen completely before using it as the basis for tests or treatments.
Compare vaccinated populations against matched unvaccinated groups receiving inert placebos.
Pre-register trial primary outcomes and do not change them mid-study.
Disclose financial relationships between advisers and manufacturers.
Investigate non-viral explanations that are present in the evidence before ruling them out.
Distinguish between deaths from a disease and deaths of people who test positive for a related marker.

None of these requirements is radical. All of them were routinely unmet in the major epidemic responses documented here.

Where these ideas come from

The ideas in this section of the knowledge base originate from the work of Torsten Engelbrecht, Dr. Claus Köhnlein MD, Dr. Samantha Bailey MD, and Dr. Stefano Scoglio BSc PhD, specifically Virus Mania, published by Trafford Publishing on 22 April 2021. Engelbrecht is an investigative journalist and medical author who has written extensively on pharmaceutical industry practices and epidemic science. Köhnlein is a German internist with clinical experience treating patients diagnosed with AIDS, hepatitis C, and COVID-19 who declined standard pharmaceutical protocols. Bailey is a New Zealand physician and science researcher. Scoglio is an Italian biochemist. The book draws on primary scientific literature, regulatory documents, pharmaceutical trial data, and on-record statements from virologists, epidemiologists, and regulatory scientists. If you want to engage with the full argument and its source citations, the original work is worth reading directly.

The knowledge base itself is an independent work. Every concept has been studied, rewritten from scratch, and restructured for use in a multi-source advisory system. Nothing from the original has been reproduced. The knowledge has been transformed, not copied. The source is named clearly because the ideas deserve proper credit, and because the original work stands on its own merits.